Navigating US FDA Post-Market Compliance and Pharmacovigilance in 2026: A Strategic Guide for Life Science Organizations
Introduction
The global pharmaceutical landscape is undergoing unprecedented regulatory transformation. As health authorities accelerate the adoption of digital technologies, real-world evidence (RWE), and stringent signal detection frameworks, maintaining compliance in high-value markets like the United States demands proactive operational resilience.
For biopharmaceutical companies and...
